Narrow-moat Grifols has strong cost advantages in the global plasma market.
Grifols has agreed to purchase partner Hologic’s share in their blood and plasma screening business for $1.85 billion in cash. We don’t expect any significant changes to our valuations for either firm following the deal. The move appears to come at a fair price and strategically fits Grifols’ desire to vertically integrate its diagnostics business while allowing Hologic to exit a business that wasn’t synergistic with the rest of its diagnostics efforts. The deal is expected to close in the first...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.